CY1122015T1 - Παραγωγο αζολιου βενζολιου - Google Patents
Παραγωγο αζολιου βενζολιουInfo
- Publication number
- CY1122015T1 CY1122015T1 CY20191100944T CY191100944T CY1122015T1 CY 1122015 T1 CY1122015 T1 CY 1122015T1 CY 20191100944 T CY20191100944 T CY 20191100944T CY 191100944 T CY191100944 T CY 191100944T CY 1122015 T1 CY1122015 T1 CY 1122015T1
- Authority
- CY
- Cyprus
- Prior art keywords
- disease
- xanthine oxidase
- disease including
- salt
- compound
- Prior art date
Links
- YZKAGUHQYDCQOL-UHFFFAOYSA-N 2-benzyl-1h-pyrrole Chemical class C=1C=CC=CC=1CC1=CC=CN1 YZKAGUHQYDCQOL-UHFFFAOYSA-N 0.000 title 1
- 108010093894 Xanthine oxidase Proteins 0.000 abstract 2
- 102100033220 Xanthine oxidase Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010007027 Calculus urinary Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 208000010380 tumor lysis syndrome Diseases 0.000 abstract 1
- 208000008281 urolithiasis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει: ένωση που αναπαριστάται από τον τύπο (I) ή φαρμακευτικώς αποδεκτό άλας αυτής, που διαθέτει εξαιρετική ανασταλτική δράση επί της οξειδάσης της ξανθίνης και χρησιμεύει ως θεραπευτικός παράγοντας ή προφυλακτικός παράγοντας για νοσήματα που σχετίζονται με την οξειδάση της ξανθίνης, όπως ουρική νόσος, υπερουριχαιμία, σύνδρομο λύσης όγκου, λιθίαση ουροφόρων οδών, υπέρταση, δυσλιπιδαιμία, διαβήτης, καρδιαγγειακά νοσήματα περιλαμβανομένων αρτηριοσκλήρυνσης και καρδιακής ανεπάρκειας, νεφρικά νοσήματα περιλαμβανομένης διαβητικής νεφροπάθειας, αναπνευστικά νοσήματα περιλαμβανομένης χρόνιας αποφρακτικής πνευμονοπάθειας, φλεγμονώδης πάθηση του εντέρου ή αυτοάνοσα νοσήματα• και φάρμακο ή φαρμακευτική σύνθεση που εμπεριέχει την ένωση ή το άλας ως δραστικό συστατικό.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013017167 | 2013-01-31 | ||
| PCT/JP2014/052154 WO2014119681A1 (ja) | 2013-01-31 | 2014-01-30 | アゾールベンゼン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122015T1 true CY1122015T1 (el) | 2020-10-14 |
Family
ID=51262388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100944T CY1122015T1 (el) | 2013-01-31 | 2019-09-10 | Παραγωγο αζολιου βενζολιου |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9388174B2 (el) |
| EP (1) | EP2952513B1 (el) |
| JP (1) | JP5734532B2 (el) |
| KR (1) | KR102199258B1 (el) |
| CN (1) | CN104968662B (el) |
| AR (1) | AR095098A1 (el) |
| AU (1) | AU2014213396B2 (el) |
| BR (1) | BR112015018033B1 (el) |
| CA (1) | CA2897928C (el) |
| CL (1) | CL2015002117A1 (el) |
| CY (1) | CY1122015T1 (el) |
| DK (1) | DK2952513T3 (el) |
| ES (1) | ES2744817T3 (el) |
| HR (1) | HRP20191554T1 (el) |
| HU (1) | HUE047028T2 (el) |
| IL (2) | IL239940B (el) |
| LT (1) | LT2952513T (el) |
| MA (1) | MA38295B1 (el) |
| ME (1) | ME03516B (el) |
| MX (1) | MX364483B (el) |
| MY (1) | MY181731A (el) |
| NZ (1) | NZ709407A (el) |
| PE (1) | PE20151329A1 (el) |
| PH (2) | PH12015501640A1 (el) |
| PL (1) | PL2952513T3 (el) |
| PT (1) | PT2952513T (el) |
| RS (1) | RS59371B1 (el) |
| RU (1) | RU2641891C2 (el) |
| SA (1) | SA515360829B1 (el) |
| SG (1) | SG11201505993PA (el) |
| SI (1) | SI2952513T1 (el) |
| SM (1) | SMT201900577T1 (el) |
| TW (1) | TWI606048B (el) |
| UA (1) | UA117124C2 (el) |
| WO (1) | WO2014119681A1 (el) |
| ZA (1) | ZA201505240B (el) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2857687T3 (es) | 2013-01-31 | 2021-09-29 | Vertex Pharma | Piridona amidas como moduladores de los canales de sodio |
| CA2931550C (en) | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| US20170217948A1 (en) | 2014-07-30 | 2017-08-03 | Teijin Pharma Limited | Xanthine oxidase inhibitor |
| TR201902314T4 (tr) * | 2014-07-30 | 2019-03-21 | Teijin Pharma Ltd | Azol benzen türevi ve bunun kristali. |
| RS57797B1 (sr) | 2014-07-30 | 2018-12-31 | Teijin Pharma Ltd | Kristal derivata azol benzena kao inhibotor ksantin oksidaze |
| US11344539B2 (en) | 2016-02-19 | 2022-05-31 | National University Corporation Tottori University | Therapeutic or prophylactic drug for dementia |
| AU2017364804A1 (en) * | 2016-11-28 | 2019-05-02 | Teijin Pharma Limited | Therapeutic drug or prophylactic drug for diabetic nephropathy |
| EP3625214B1 (en) | 2017-05-16 | 2022-07-06 | Vertex Pharmaceuticals Incorporated | Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels |
| WO2019157505A1 (en) | 2018-02-12 | 2019-08-15 | Vertex Pharmaceuticals Incorporated | A method of treating pain |
| MX2022006865A (es) | 2019-12-06 | 2022-07-11 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. |
| CN117794920A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂 |
| WO2023122780A2 (en) * | 2021-12-23 | 2023-06-29 | The Katholieke Universiteit Leuven | 2-pyrazole anilines and related analogs for inhibiting yap/taz-tead |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122008000051I1 (de) | 1990-11-30 | 2009-02-05 | Teijin Ltd | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel |
| KR100308332B1 (ko) * | 1995-04-07 | 2002-09-17 | 데이진 가부시키가이샤 | 기관또는조직보호제 |
| RU2135493C1 (ru) * | 1995-04-21 | 1999-08-27 | Нюросерч А/С | Производное бензимидазола, фармацевтический состав и способ модуляции гамка-рецепторного комплекса |
| JP2002105067A (ja) | 2000-09-28 | 2002-04-10 | Teijin Ltd | ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物 |
| EP1932833B1 (en) | 2005-10-07 | 2012-08-01 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| WO2008126770A1 (ja) * | 2007-04-05 | 2008-10-23 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体の製造方法 |
| CN101679244B (zh) | 2007-04-11 | 2014-01-01 | 橘生药品工业株式会社 | 5元杂环衍生物及其医药用途 |
| WO2010018458A2 (en) | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
| WO2010128163A2 (en) | 2009-05-08 | 2010-11-11 | Pike Pharma Gmbh | Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication |
| WO2011101867A2 (en) | 2010-02-19 | 2011-08-25 | Cadila Healthcare Limited | Substantially pure salts of febuxostat and processes for preparation thereof |
| US8969582B2 (en) | 2010-04-29 | 2015-03-03 | Dr. Reddy's Laboratories Ltd. | Preparation of febuxostat |
-
2014
- 2014-01-29 TW TW103103559A patent/TWI606048B/zh active
- 2014-01-30 LT LT14746209T patent/LT2952513T/lt unknown
- 2014-01-30 PE PE2015001576A patent/PE20151329A1/es active IP Right Grant
- 2014-01-30 NZ NZ70940714A patent/NZ709407A/en not_active IP Right Cessation
- 2014-01-30 CN CN201480006601.1A patent/CN104968662B/zh active Active
- 2014-01-30 MX MX2015009655A patent/MX364483B/es active IP Right Grant
- 2014-01-30 SM SM20190577T patent/SMT201900577T1/it unknown
- 2014-01-30 MY MYPI2015702266A patent/MY181731A/en unknown
- 2014-01-30 DK DK14746209.7T patent/DK2952513T3/da active
- 2014-01-30 PT PT14746209T patent/PT2952513T/pt unknown
- 2014-01-30 ME MEP-2019-262A patent/ME03516B/me unknown
- 2014-01-30 RS RSP20191244 patent/RS59371B1/sr unknown
- 2014-01-30 PL PL14746209T patent/PL2952513T3/pl unknown
- 2014-01-30 AU AU2014213396A patent/AU2014213396B2/en active Active
- 2014-01-30 EP EP14746209.7A patent/EP2952513B1/en active Active
- 2014-01-30 WO PCT/JP2014/052154 patent/WO2014119681A1/ja not_active Ceased
- 2014-01-30 HU HUE14746209A patent/HUE047028T2/hu unknown
- 2014-01-30 RU RU2015132105A patent/RU2641891C2/ru active
- 2014-01-30 KR KR1020157019782A patent/KR102199258B1/ko active Active
- 2014-01-30 CA CA2897928A patent/CA2897928C/en active Active
- 2014-01-30 SG SG11201505993PA patent/SG11201505993PA/en unknown
- 2014-01-30 US US14/442,752 patent/US9388174B2/en active Active
- 2014-01-30 MA MA38295A patent/MA38295B1/fr unknown
- 2014-01-30 BR BR112015018033-7A patent/BR112015018033B1/pt active IP Right Grant
- 2014-01-30 HR HRP20191554 patent/HRP20191554T1/hr unknown
- 2014-01-30 AR ARP140100314A patent/AR095098A1/es unknown
- 2014-01-30 SI SI201431281T patent/SI2952513T1/sl unknown
- 2014-01-30 JP JP2014557920A patent/JP5734532B2/ja not_active Expired - Fee Related
- 2014-01-30 UA UAA201507650A patent/UA117124C2/uk unknown
- 2014-01-30 ES ES14746209T patent/ES2744817T3/es active Active
-
2015
- 2015-07-14 IL IL239940A patent/IL239940B/en active IP Right Grant
- 2015-07-21 ZA ZA2015/05240A patent/ZA201505240B/en unknown
- 2015-07-23 PH PH12015501640A patent/PH12015501640A1/en unknown
- 2015-07-29 SA SA515360829A patent/SA515360829B1/ar unknown
- 2015-07-29 CL CL2015002117A patent/CL2015002117A1/es unknown
-
2018
- 2018-02-05 PH PH12018500261A patent/PH12018500261B1/en unknown
- 2018-06-05 IL IL259824A patent/IL259824B/en active IP Right Grant
-
2019
- 2019-09-10 CY CY20191100944T patent/CY1122015T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500261A1 (en) | Azole benzene derivative | |
| EA201591291A1 (ru) | Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания | |
| BR112012033715A2 (pt) | inibidores de quinase de regulação de sinal de apoptose. | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| WO2012177481A3 (en) | Fibroblast growth factor receptor inhibition for the treatment of disease | |
| TR201905814T4 (tr) | Jak inhibitörü olarak bipirazol tuzu. | |
| ME03016B (me) | Derivat piridina | |
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| PH12012502447A1 (en) | Tetrahydrocarboline derivative | |
| WO2014126944A3 (en) | Inhibitors of the renal outer medullary potassium channel | |
| CY1122760T1 (el) | Τροποποιητης εξενατιδης και χρηση αυτου | |
| MX2020011818A (es) | Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos. | |
| MX2017012295A (es) | Derivados formilados n-heterociclicos como inhibidores de fgfr4. | |
| HK1257555A1 (zh) | Tec激酶家族之抑制剂 | |
| EA201890532A1 (ru) | Новые аннелированные бензамиды | |
| WO2015095097A3 (en) | Inhibitors of the renal outer medullary potassium channel | |
| MX2017000635A (es) | Inhibidores del canal de potasio medular externo renal. | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| CY1120672T1 (el) | Παραγωγο πυραζολης | |
| MX2017000634A (es) | Inhibidores del canal de potasio medularmente externo renal. | |
| EA201171125A1 (ru) | Антагонист минералокортикоидного рецептора и способы его применения | |
| BR112020010149A8 (pt) | Derivado de pirimidina sulfamida e método de preparação e aplicação médica | |
| MX2019011639A (es) | Formulacion farmaceutica. | |
| BR112018003335A2 (pt) | composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona | |
| AR101364A1 (es) | Derivado de ácido azolcarboxílico |